Clinical trials
Completed Myeloproliferative Disorders trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2003 | 1 |
| 2005 | 3 |
| 2007 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 5 |
| Novartis Pharmaceuticals | 4 |
| FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Icahn School of Medicine at Mount Sinai | 2 |
| Incyte Corporation | 2 |
| AUSL Romagna Rimini | 1 |
| Advice Pharma Group srl | 1 |
| Celgene | 1 |
| Constellation Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myeloproliferative Disorders | 28 |
| Primary Myelofibrosis | 13 |
| Leukemia, Myeloid, Acute | 10 |
| Polycythemia Vera | 10 |
| Multiple Myeloma | 9 |
| Thrombocythemia, Essential | 9 |
| Hodgkin Disease | 8 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
| Burkitt Lymphoma | 7 |
| Immunoblastic Lymphadenopathy | 7 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.